Abstract
Background:
Psilocybin-induced mystical-type experiences are associated with lasting positive psychological outcomes. Recent studies indicate that trait mindfulness is increased 3 months after psilocybin intake, preceded by decreases in neocortical serotonin 2A receptor (5-HT2AR) binding. However, the association between psilocybin-induced mystical-type experiences and subsequent changes in trait mindfulness remains unexplored, as does the association between pre-drug trait mindfulness and 5-HT2AR binding in the healthy brain.
Aim:
We evaluated whether psilocybin induced lasting increases in trait mindfulness in healthy volunteers, and whether the mystical-type experience was associated with this increase. We further examined the association between pre-drug trait mindfulness and 5-HT2AR binding in neocortex and selected frontolimbic regions.
Materials and methods:
Forty-six medium-high dose psilocybin sessions were conducted in 39 healthy individuals. The mystical-type experience was measured with the Mystical Experience Questionnaire (MEQ) at the end of the session. Trait mindfulness was measured using the Mindful Attention and Awareness Scale (MAAS) at baseline and 3 months after the psilocybin session. Thirty-two of the participants completed pre-drug [11C]-Cimbi-36 positron emission tomography (PET) to assess 5-HT2AR binding in neocortex and, post-hoc, in the frontolimbic regions amygdala, frontal cortex, and anterior cingulate cortex.
Results:
The MAAS score was significantly increased at 3-month follow-up (p = 3.24 × 10–6), a change positively associated with the MEQ score (p = 0.035). Although the association between pre-drug MAAS score and neocortex 5-HT2AR binding was not significant (p = 0.24), post-hoc analyses revealed a significant negative association between MAAS and right amygdala 5-HT2AR binding (pFWER = 0.008).
Conclusion:
We here show that lasting changes in trait mindfulness following psilocybin administration are positively associated with intensity of the mystical-type experience, suggesting that the acute phenomenology of psilocybin facilitates a shift in awareness conducive for mindful living. We furthermore show that higher pre-drug trait mindfulness is associated with reduced 5-HT2AR binding in the right amygdala.
Introduction
Psilocybin is a tryptamine alkaloid, naturally present in the Psilocybe genus of mushrooms, currently being researched as a promising therapeutic agent for a range of psychiatric disorders (; ). In clinical studies, psilocybin shows immediate and sustained effects on depression (, , ; ), obsessive-compulsive disorder (), anxiety and depression in terminal cancer patients (; ; ), alcohol abuse (; ) and smoking (, ). With increasing evidence in favor of positive effects of psilocybin, it is crucial to explore potential associated psychological factors. A small (n = 10) study has recently demonstrated increases in trait mindfulness in healthy individuals 3 months following a psilocybin session with no related mindfulness-training (). Similarly, significant increases in trait mindfulness have been observed as soon as 24 h after psilocybin intake in experienced meditators compared to placebo (). Trait mindfulness can be defined as “the awareness that emerges through paying attention on purpose, in the present moment, and non-judgmentally to the unfolding of experience moment by moment.” (, p. 145). It is positively associated with trait openness (), improved behavioral regulation () and positive bias (), and negatively associated with trait neuroticism (), emotional reactivity () and negative bias (), suggesting that higher trait mindfulness is an indicator of greater psychological health. Several techniques to evoke a state of mindfulness stem from Buddhist meditation (; ), and have been integrated as components of third-wave cognitive behavior therapy, such as Acceptance and Commitment Therapy (ACT) (), Mindfulness Based Cognitive Therapy (MBCT) () and Mindfulness Based Stress Reduction (MBSR) (), so called mindfulness-based interventions (MBI’s). Several researchers have postulated MBI as a framework for psychedelic drug administration due to similar phenomenology and psychological benefits that may act synergistically in combination (; ; ). However, more empirical data is needed to gain a better understanding of how acute psychoactive effects of psilocybin are potentially associated with changes in trait mindfulness.
The psychoactive metabolite of psilocybin, psilocin, dose-dependently activates the serotonin 2A receptor (5-HT2AR) (; ; ), alters cerebral functional network changes (; ) and induces an altered state of consciousness characterized by three phases: ascent, peak and descent, lasting 4–6 h (; ; ). The psilocybin-induced psychedelic experience has a unique phenomenology, including effects such as altered visual and auditory perception, audio-visual synesthesia, enhanced emotions and meaning-making and changes in sense of self (). Interestingly, when administered in medium-to-high doses (>12 mg), psilocybin can induce a highly meaningful experience (, ) known as the mystical-type experience, characterized as an experience of unity with all that exists, a sense of awareness of the fundamental truths of reality, deepfelt blissful mood, transcendence of space and time and difficulty describing the experience with words, termed ineffability (; ; ). Having a mystical-type experience during psilocybin administration has been associated with persistent positive effects () and increases in trait openness () in healthy volunteers, as well as improvements in symptoms in psychiatric patient populations (; ; ; ; ; ). The psilocybin-induced mystical-type experience shares many phenomenological features with mindful states, including altered self-referential processing (). It is therefore possible that having a mystical experience in the context of psilocybin administration could be a catalyst for lasting changes in trait mindfulness.
We have recently reported a significant negative association between changes in neocortical 5-HT2AR binding 1 week after psilocybin administration and changes in trait mindfulness after 3 months (), suggesting an involvement of 5-HT2AR in trait mindfulness. We also found that lower pre-drug 5-HT2AR binding, i.e., unstimulated by psilocybin, predicted the temporal unfolding of psychoactive effects of psilocybin, including greater intensity of the mystical-type experience (). 5-HT2AR binding in selected frontolimbic brain regions has previously been positively associated to trait neuroticism (), a trait inversely related to trait mindfulness (; ; ). Given that 5-HT2AR is critical for the described mind-expanding effects of psilocybin (; ), it is conceivable that 5-HT2AR may be involved in mindful and meditative states that are often also described as expanded states (; ). However, the association between pre-drug 5-HT2AR binding and trait mindfulness has not yet been investigated.
In the present study, we evaluate the effect of psilocybin on changes in trait mindfulness from baseline to 3-month follow-up, and whether the mystical-type experience during acute psilocybin administration is associated with these changes in trait mindfulness. Lastly, we explore whether pre-drug 5-HT2AR binding in neocortex and frontolimbic regions is associated with trait mindfulness. We hypothesize that: (1) Trait mindfulness will increase from baseline to 3-month following psilocybin administration, (2) The intensity of the mystical-type experience is positively associated with changes in trait mindfulness, and (3) Pre-drug 5-HT2AR binding in neocortex and frontolimbic regions is negatively associated with trait mindfulness.
Materials and methods
Participants
The study included 39 participants who received a psychoactive psilocybin dose (>12 mg) and completed baseline and 3-month follow-up measures of trait mindfulness, as well as a post-session measure of the mystical-type experience. Of these, seven participants completed two psilocybin interventions with new baseline and follow-up measures, at least 12 months apart (mean months between interventions (SD) [range]: 21 (5) [12–28]). Thus, in order to increase power for the analyses, a total of 46 datasets were included in the analyses pertaining to hypotheses (1) and (2). For the analyses pertaining to hypothesis (3), 32 of the included participants also completed a pre-drug Positron Emission Tomography (PET) scan with the tracer [11C]-Cimbi-36 for imaging of 5-HT2AR binding in neocortex and frontolimbic regions (, ).
All participants were recruited from a database of individuals volunteering to participate in human neuroimaging studies of psilocybin. Exclusion criteria included (a) present or previous psychiatric disorder in participant or immediate family, (b) present or previous neurological illness, severe somatic illness, or present medication that could affect the results, (c) non-fluency in Danish, vision or hearing impairment, (d) Present or previous learning disabilities, (e) current pregnancy or breastfeeding for women, (f) contraindications for MR-imaging, (g) alcohol or drug abuse, (h) allergy to the test drugs, (i) significant exposure to radioactivity within the past year, e.g., due to medical imaging, (j) ECG indicative of cardiac disease or use of medication causing prolonged QT-interval, (k) previous negative side-effects from hallucinogens, (l) use of psychedelics in the past 6 months, (m) blood donation less than 3 months before project participation, (n) hemoglobin <7.8 mM for women and 8.4 mM for men, (o) low plasma ferritin (<12 μg/L) and (p) bodyweight <50 kg. This was ensured through a complete physical and neurological exam, including ECG and blood screening for pathology, and a psychiatric screening, using the Mini International Neuropsychiatric Interview ().
Experimental procedures
Psilocybin interventions
Prior to the intervention day, participants met with the psychological support staff (one trained lead psychologist and one psychology trainee) to prepare for the psilocybin intervention, which included being informed about potential side-effects and safety precautions. On the intervention day, psilocybin was administered orally in 3 mg capsules with a glass of water based on a maximum weight-adjusted dose of 0.21 mg/kg (n = 12 sessions) or 0.31 mg/kg (n = 34 sessions). Of the 46 psilocybin interventions, 6 took place partly in a PET-scanner during acute effects (); 18 took place in a comfortable and private room (), and 22 took place partly in a MR-scanner during acute effects (). The psychological support staff members were present with the participant throughout the intervention day to provide interpersonal support. All participants met with the psychological support staff the day after intervention for an integration session. All preparation and integration sessions were standardized across interventions and were conducted by the same lead psychologist.
Outcome measures
Mindful Attention and Awareness Scale
We used the Danish version of the Mindful Attention and Awareness Scale (MAAS) () to assess the participants’ trait mindfulness at baseline and 3 months after the psilocybin intervention. The MAAS is a self-report scale, comprising 15 items related to general tendencies of inattentiveness toward emotions, thought, activities and physical sensations in the everyday experience, rated on a six-point Likert scale from one (almost always) to six (almost never). Example items include “I find it difficult to stay focused on what’s happening in the present” and “I find myself preoccupied with the future or the past.” The total MAAS score is calculated as the mean of all 15 items. Higher scores indicate higher degrees of trait mindfulness. The MAAS has a unidimensional construct with excellent internal consistency (Cronbach’s alpha for this dataset: baseline α = 0.86, follow-up α = 0.90) and good test-rest reliability (; ).
Mystical Experience Questionnaire
Approximately 6 h after psilocybin administration on the intervention day, participants completed the Danish version of the 30-item version of the Mystical Experience Questionnaire (MEQ) (). The MEQ is a self-report scale to assess the intensity of mystical experience related to a discrete event, such as during acute psilocybin effects. Participants rated each item on a 6-point Likert scale [0 = none at all, 5 = extreme (more than ever before in my life and stronger than 4)] on four subscales: mystical (e.g., “freedom from the limitations of your personal self and feeling of unity or bond with what was felt to be greater than your personal self”), positive mood (e.g., “experience of ecstasy”), transcendence of time and space (e.g., “loss of your usual sense of time”) and ineffability (e.g., “feeling that you could not do justice to your experience by describing it in words”). The total MEQ score is calculated as the mean of all items.
Positron Emission Tomography and Magnetic Resonance Imaging
Thirty-two participants were scanned at baseline using High Resolution Research Tomography PET scanner (CTI/Siemens, Knoxville, USA) with an approximate in-plane resolution of 2 mm for 120 min after a bolus injection of [11C]-Cimbi-36 tracer to reflect and image 5-HT2AR binding (, ). The scans were reconstructed into 45 frames (6 × 10 s, 6 × 20 s, 6 × 60 s, 8 × 120 s, 19 × 300 s). For the purpose of PET-image co-registration and segmentation, high resolution 3D T1-weighted and T2-weighted images were acquired on a 3T prisma magnetic resonance imaging (MRI) Scanner (Siemens, Erlangen, Germany), using either a 64-channel or a 32-channel head coil. Regional time-activity curves including cerebellum as a reference region were extracted, as previously described (), and kinetic modeling was done using the simplified reference tissue model (SRTM) to compute the regional non-displaceable binding potential (BPND) (, ). Neocortical (a volume-weighted average of all cortical regions) [11C]-Cimbi-36 BPND was chosen as our primary outcome region based on findings from our previous study (), the high expression of 5-HT2AR within neocortex () and the high degree of inter-regional correlation across neocortical subregions (; ). As secondary outcomes for post-hoc analyses, [11C]-Cimbi-36 BPND in frontolimbic regions [frontal cortex, left and right amygdala and left and right anterior cingulate cortex (ACC)] were chosen based on a previous study ().
Data analysis
Psilocybin, Mystical Experience Questionnaire, and change in Mindful Attention and Awareness Scale
To evaluate the change in MAAS score from baseline to 3-month follow-up after psilocybin administration (Hypothesis 1) and its association with MEQ total score (Hypothesis 2), we used a linear mixed-effect model (LMM) for each hypothesis, as this model accounts for the repeated measures. To account for the seven participants who had completed two psilocybin interventions, participant-ID was included as a random effect. Baseline MAAS score was included as a covariate for Hypothesis 2, as magnitude of the change naturally is dependent on the baseline MAAS score due to the upper limit of the scale being six, and baseline MAAS has been associated to change in MAAS following a mindfulness-intervention (). Although psilocybin dose and setting () have been associated with acute psychedelic effects and positive psychological outcomes, inclusion of these as covariates in our model did not substantially affect the results, and were therefore not included in the final analyses. We report change in MAAS as the percentage change with a 95% confidence interval.
Post-hoc analysis of Mystical Experience Questionnaire subscales and change in Mindful Attention and Awareness Scale
In post-hoc analyses, we examined associations between change in MAAS and the individual MEQ subscales mystical, positive mood, transcendence of time and space, and ineffability, using the same LMM and under the same conditions presented in section “Psilocybin, Mystical Experience Questionnaire, and change in Mindful Attention and Awareness Scale.”
Pre-drug neocortical [11C]-Cimbi-36 binding and Mindful Attention and Awareness Scale
To evaluate the association between pre-drug neocortical [11C]-Cimbi-36 BPND and MAAS score, (Hypothesis 3) we fit a linear regression model with [11C]-Cimbi-36 BPND as independent variable and MAAS score as the dependent variable. Given that MAAS score is associated to age () and body mass index (BMI) (), these were included as covariates. Effects for the models are reported as unstandardized regression coefficients (β) with 95% confidence intervals (95% CI) and adjusted R2 as a measure of variance.
Post-hoc analyses of pre-drug frontolimbic [11C]-Cimbi-36 binding and Mindful Attention and Awareness Scale
In post-hoc analyses, we evaluated the associations between pre-drug [11C]-Cimbi-36 BPND in the frontolimbic brain regions (total frontal cortex and right and left amygdala and ACC) and MAAS score. Covariates and procedures for reporting effects for the models were identical to those presented in section “Pre-drug neocortical [11C]-Cimbi-36 binding and Mindful Attention and Awareness Scale.”
Statistical significance and effect size
For Hypothesis 1, we conducted two significance tests: one with (n = 46) and one without the 10 participants from our previous study (n = 36) (), to demonstrate an independent replication. Cohen’s d is reported as an expression of standardized effect size () for Hypothesis 1. The threshold for statistical significance for Hypothesis 1, 2 and 3 was p < 0.05. For the post-hoc analyses, p-values were corrected for multiple tests using the Bonferroni method; four tests for the post-hoc analyses regarding the MEQ subscales, and five tests for the post-hoc analyses regarding pre-drug [11C]-Cimbi-36 BPND in frontolimbic regions. For post-hoc analyses, p-values are reported both uncorrected (punc) and with a family-wise error rate correction (pFWER) using a statistical threshold of pFWER < 0.05. All statistical analyses were conducted using the statistical software R (v4.0.5).
Results
Participant characteristics and descriptive statistics
Participant characteristics and descriptive data are summarized in Table 1. Previous psychedelic use covers prior experience with 5-HT2AR agonistic psychedelics. A figure graphically displaying the change in each MAAS item score from baseline to 3-month follow-up can be found in Supplementary Figure 1.
TABLE 1
| Variables | Mean ± SD | Median | Range: min, max |
| Interventions n = 46 | |||
| Sex (% female) | 37 | ||
| Previous psychedelic use (% yes) | 37 | ||
| Age (years) | 32.6 ± 8.69 | 29.8 | 24.2, 60.2 |
| BMI (kg/m2)* | 24.5 ± 3.09 | 23.8 | 18.8, 33.2 |
| Weight-adjusted psilocybin dose (mg/kg) | 0.26 ± 0.04 | 0.27 | 0.15, 0.32 |
| Actual psilocybin dose (mg) | 20.2 ± 4.36 | 21 | 12, 30 |
| Time from psilocybin intervention to follow-up MAAS score (months) | 3.21 ± 0.55 | 3.10 | 2.55, 5.35 |
| Baseline MAAS score | 4.14 ± 0.6 | 4.2 | 2.33, 5.13 |
| Neocortical [11C]-Cimbi-36 BPND** | 1.21 ± 0.220 | 1.17 | 0.870, 2.02 |
Participant characteristics and descriptive statistics.
*For the participants that participated in two interventions, only BMI from the first intervention is included (n = 39), as only PET data from the first intervention was included in Hypothesis 3, where BMI was used as a covariate. **n = 32.
Changes in Mindful Attention and Awareness Scale following psilocybin administration
We found a significant increase in average MAAS score from baseline to 3-month follow-up, both in the full sample (n = 46) (Cohen’s d: 0.72; mean% change [95%CI]: 8.1 [5.1;11.1]; p = 3.24 × 10–6, Figure 1) and in the independent sample (n = 36) (Cohen’s d: 0.71; mean% change [95%CI]: 7.5 [4.0;10.9]; p = 1.0 × 10–4). A graphical display of relation between baseline MAAS and change in MAAS is illustrated in Supplementary Figure 2.
FIGURE 1
Mystical Experience Questionnaire and change in Mindful Attention and Awareness Scale
MEQ total score was significantly positively associated with change in MAAS score (% mean change per unit increase in MEQ [95%CI]: 3.1 [0.04; 6.0]; p = 0.035, Figure 2).
FIGURE 2
Post-hoc: Mystical Experience Questionnaire subscales and changes in Mindful Attention and Awareness Scale
Post-hoc analyses revealed a statistically significant positive association between change in MAAS score and the MEQ subscale mystical (% mean change per unit increase in mystical [95%CI]: 2.93 [0.75; 5.11]; punc = 0.012, pFWER = 0.049). No other significant associations between change in MAAS score and MEQ subscales were observed after correction for multiple testing (positive mood: 3.40 [0.67; 6.13]; punc = 0.019, pFWER = 0.076, transcendence of time and space: 0.48 [−2.57; 3.57]; punc = 0.75, pFWER = 3 and ineffability: −0.13 [−3.01; 2.76]; punc = 0.93, pFWER = 3.72).
Pre-drug neocortical [11C]-Cimbi-36 BPND and Mindful Attention and Awareness Scale
The linear regression model showed a negative but not significant association between pre-drug neocortical [11C]-Cimbi-36 BPND and MAAS score (β [95%CI], R2: −0.55 [−1.48; 0.38], 0.0051; p = 0.24).
Post-hoc: Pre-drug frontolimbic [11C]-Cimbi-36 BPND and Mindful Attention and Awareness Scale
Post-hoc analyses revealed a significant negative association between pre-drug right amygdala [11C]-Cimbi-36 BPND and MAAS score (β [95%CI], R2: −0.67 [–1.06; −0.28], 0.30; punc = 0.0016, pFWER = 0.008, Figure 3). No other significant associations between [11C]-Cimbi-36 BPND in frontolimbic regions and MAAS score were observed after correction for multiple testing (frontal cortex: −0.48 [−1.35; 0.38], 0.00015; punc = 0.26, pFWER = 1.3), right ACC: −0.19 [−1.54; 0.17], −0.0047; punc = 0.29, pFWER = 1.45, left ACC: −0.31 [−0.90; −0.28], – 0.0056; punc = 0.30, pFWER = 1.5 and left amygdala: (−0.14 [−1.71; −0.89], −0.05; punc = 0.78, pFWER = 3.9).
FIGURE 3
Discussion
We here demonstrate that psilocybin induces a significant increase in trait mindfulness of 8.1% from baseline to 3-month follow-up across 46 psilocybin sessions. As a novel finding, we show that participants who experienced a greater mystical-type experience exhibited a significantly greater increase in trait mindfulness at 3-month follow-up. We found no significant association between pre-drug neocortical 5-HT2AR binding and trait mindfulness; however, post-hoc analyses of frontolimbic brain regions revealed a significant negative association between pre-drug 5-HT2AR binding in the right amygdala and trait mindfulness.
The observed increase in trait mindfulness replicates and strengthens the results of our previous study, where psilocybin increased trait mindfulness for at least 3 months in 10 healthy volunteers (). These findings align with previous studies of psychedelic-induced mindfulness in healthy volunteers. Buddhist meditation practitioners show increased trait mindfulness the day after psilocybin compared to placebo (), and ayahuasca intake is associated with increased mindfulness 24 h after administration (; ). More sustained effects have only been studied after 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) intake where trait mindfulness was higher 1 month after intake (). Taken together, there is a growing amount of evidence suggesting that psychedelic substances promote an immediate and sustained increase in trait mindfulness in healthy individuals.
Although trait mindfulness is considered a stable human disposition, it can be enhanced through meditation and mindfulness-practice (). Our findings of sustained and increased trait mindfulness following psilocybin administration can be interpreted in relation to a previous mindfulness-intervention, where healthy individuals participated in an 8-week intensive MBSR course and on average experienced a 7% increase in trait mindfulness, compared to 1–3% in the inactive control groups (), indicating a significant increase following MBSR training. Another MBSR study reported a sustained 8% increase in trait mindfulness over 12-months in the treatment group, compared to the control group where both increases and decreases in trait mindfulness were reported, fluctuating up to 7% in each direction (). These results suggest that trait mindfulness naturally fluctuates over time, but on average at a lower magnitude and without a clear pattern compared to what is observed following MBSR treatment and psilocybin intervention, the latter as suggested by the results from the current study.
Our findings support a positive association between the intensity of the mystical-type experience and increases in trait mindfulness, echoing previous studies that have attested to the importance of the mystical-type experience for lasting positive psychological effects of psilocybin (; ; ; ; , ; ; ; ; ; ). In self-reported psilocybin accounts, healthy participants who have had a complete mystical-type experience (>60% on all subscales of the MEQ) describe feeling a universal bond, witnessing profound beauty and a great love for family (). These themes of connectedness, bliss and unity with all things are also recounted in mindfulness practice, such as meditation (; ). Other notable parallels with meditation include the experience of ego-dissolution (; ; ) along with neurobiological similarities, such as reduced network integrity in the default mode network (; ; ; ). Furthermore, it has recently been demonstrated that both trait mindfulness and mystical-type experiences are associated with greater mental wellbeing, and that specifically psilocybin-induced mystical-type experiences alongside a mindfulness practice are associated with higher mindfulness and greater mental wellbeing (). It is possible that the subjective experience of merging with a “oneness” of all things together with a diminished focus on ego, at least when combined with a blissful or ecstatic emotional tone, allows for a shift in perspective that is conducive for psychological flexibility and mindful living. This is further supported by our post hoc finding of a significant positive association between the MEQ subscale “mystical” and change in trait mindfulness. Based on these initial findings, we encourage future research to study the possible complimentary effects of mindfulness-practice and psilocybin in clinical populations, as it may be a suitable therapeutic framework to maintain positive psychological effects of psilocybin treatment. It is also conceivable that intervention with psilocybin could be used to address barriers to MBI and potentially assist individuals who struggle with engagement in therapy.
In post-hoc analyses, we found a significant negative association between pre-drug 5-HT2AR binding in the right amygdala and trait mindfulness. There is some pre-clinical evidence to suggest an inverse coupling between available serotonin in the brain and 5-HT2AR binding (), further supported by the downregulation of 5-HT2AR binding following administration of serotonergic antidepressants (; ; ), also seen in depressed patients (). As such, it is possible that lower 5-HT2AR binding in the right amygdala reflects increased serotonin, and that this is coupled to higher trait mindfulness. However, interpretation of this finding should be made with caution, as the time-activity curve fit for amygdala is typically noisy (), and we observed no other significant associations for neocortex or frontolimbic regions, including the left amygdala. Interestingly, fMRI studies support involvement of the right amygdala in mindful states () and trait mindfulness (), suggesting that the right amygdala may be more involved in mindfulness than the left amygdala. Future studies are needed to replicate the observed association between right amygdala 5-HT2AR binding and trait mindfulness, and further explore the role of serotonin for individual differences in response to psychedelic administration.
Limitations
Our findings should be interpreted in light of the following limitations: Since we did not collect data in the time that elapsed between psilocybin intervention and 3-months follow-up, we cannot determine whether follow-up MAAS scores were affected by other life circumstances during this time period. Furthermore, although MAAS has shown high test-retest reliability and is a stable personality trait measure of mindfulness (; ), this study is limited by its open-label design and not having a blinded control group (see for discussion).
Conclusion
We demonstrate that trait mindfulness is increased in healthy volunteers at least 3 months following a single psilocybin intervention and that the self-reported mystical-type experience immediately following the psychedelic experience is positively associated with this lasting increase in trait mindfulness. We also show a negative association between pre-drug 5-HT2AR binding in the right amygdala and trait mindfulness. These findings suggest that psilocybin and the mystical-type experience could have mindfulness-enhancing capacities, and may potentially work in synergy with mindfulness-based forms of therapies in a clinical setting.
Statements
Data availability statement
The datasets presented in this article are not readily available because of the General Data Protection Regulation (GDPR). However, data in the Cimbi database can be accessed by application (http://www.cimbi.dk/db). Requests to access the datasets should be directed to Peter S. Jensen, http://www.cimbi.dk/db.
Ethics statement
The studies involving human participants were reviewed and approved by the Danish Medicines Agency (EudraCT ID: 2016-004000-61, amendments: 2017014166, 2017082837, and 2018023295); and the Ethics Committee for the Capital Region of Copenhagen (journal ID: H-16028698, with amendments 56023, 56967, 57974, 59673, 60437, 62255, 74340, and 79042). This study was conducted in accordance with the Declaration of Helsinki. The participants provided their written informed consent to participate in this study.
Author contributions
AS collected the data, performed analyses, and wrote the manuscript. MM collected the data and provided feedback on the manuscript. BO provided statistical consultation. SA collected the data, assisted with the psilocybin interventions, and provided feedback on the manuscript. GK conceptualized the study, supervised the data collection, and provided feedback on the manuscript. PF collected the data, supervised the data collection, and provided feedback on the manuscript. DS conceptualized the study, assisted with the psilocybin interventions, and supervised the writing of the manuscript. All authors contributed to the article and approved the submitted version.
Funding
Data collected in the present manuscript was supported by the Innovation Fund Denmark (Grant Number 4108-00004B), Independent Research Fund Denmark (Grant Numbers 6110-00518B and 9058-00017B), and The Ester M. og Konrad Kristian Sigurdssons Dyreværns Foundation (Grant Number 850-22-55166-17-LNG). AS was supported through a stipend from The Novo Nordisk Foundation (Grant Number NNF20OC0066082). MM was supported through a stipend from Rigshospitalet’s Research Council (Grant Number R130-A5324). BO was supported by The Lundbeck Foundation (Grant Number R231-2016-3236) and Marie-Curie-NEUROMODEL (Grant Number 746850).
Acknowledgments
We extend our sincere gratitude to Peter Jensen, Dorthe Givard, Drummond McCulloch, Lone Freyr, Agnete Dyssegaard, Josephine Torp, Gerda Thomsen, Svitlana Olsen, Annette Johansen, Catharina Messel, and Maria Zofia Grzywacz for help in various aspects of data collection and analysis. We are grateful to the University of Chemistry and Technology and the National Institute of Mental Health (Prague, Czechia) for production of psilocybin and Glostrup Apotek (Glostrup, Denmark) for encapsulation. We are grateful to The John and Birthe Meyer Foundation for the donation of the Cyclotron and PET scanner.
Conflict of interest
MM has received an honorarium as a speaker for Lundbeck Pharma and the Lundbeck Foundation. DS has received an honorarium as a speaker for the Lundbeck Foundation. GK has received honoraria as a consultant for Sanos and as a speaker for Sage-Biogen. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer SL declared a shared parent affiliation with the authors to the handling editor at the time of review.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyg.2022.948729/full#supplementary-material
References
1
AndersenK. A.Carhart-HarrisR.NuttD. J.ErritzoeD. (2021). Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies.Acta Psychiatr. Scand. Scand.143101–118. 10.1111/acps.13249
2
ArmandS.OzenneB.SvartN.FrokjaerV. G.KnudsenG. M.FisherP. M.et al (2022). Brain serotonin transporter is associated with cognitive-affective biases in healthy individuals.Hum. Brain Mapp.434174–4184. 10.1002/hbm.25946
3
BaerR. A.SmithG. T.HopkinsJ.KrietemeyerJ.ToneyL. (2006). Using self-report assessment methods to explore facets of mindfulness.Assessment1327–45. 10.1177/1073191105283504
4
BarrettF. S.GriffithsR. R. (2018). “Classic hallucinogens and mystical experiences: Phenomenology and neural correlates,” in Behavioral neurobiology of psychedelic drugs. current topics in behavioral neurosciences, edsHalberstadtA. L.VollenweiderF. X.NicholsD. E. (Berlin: Springer), 393–430. 10.1007/7854_2017_474
5
BarrettF. S.JohnsonM. W.GriffithsR. R. (2015). Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.J. Psychopharmacol.291182–1190. 10.1177/0269881115609019
6
BeliveauV.GanzM.FengL.OzenneB.HøjgaardL.FisherP. M.et al (2017). A high-resolution in vivo atlas of the human brain’s serotonin system.J. Neurosci.37120–128. 10.1523/JNEUROSCI.2830-16.2016
7
BishopS. R.LauM.ShapiroS.CarlsonL.AndersonN. D.CarmodyJ.et al (2004). Mindfulness: A proposed operational definition.Clin. Psychol. Sci. Pract.11230–241. 10.1093/clipsy/bph077
8
BogenschutzM. P.ForcehimesA. A.PommyJ.WilcoxC. E.BarbosaP. C. R.StrassmanR. J. (2015). Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study.J. Psychopharmacol.29289–299. 10.1177/0269881114565144
9
BrewerJ. A.WorhunskyP. D.GrayJ. R.TangY. Y.WeberJ.KoberH. (2011). Meditation experience is associated with differences in default mode network activity and connectivity.Proc. Natl. Acad. Sci. U.S.A.10820254–20259. 10.1073/pnas.1112029108
10
BrownK. W.RyanR. M. (2003). The benefits of being present: Mindfulness and its role in psychological well-being.J. Pers. Soc. Psychol.84822–848. 10.1037/0022-3514.84.4.822
11
CamilleriG. M.MéjeanC.BellisleF.HercbergS.PéneauS. (2015). Association between Mindfulness and weight status in a general population from the NutriNet-Santé study.PLoS One10:e0127447. 10.1371/journal.pone.0127447
12
Carhart-HarrisR. L.GoodwinG. (2017). The therapeutic potential of psychedelic drugs: Past, present and future.Neuropsychopharmacology422105–2113. 10.1038/npp.2017.84
13
Carhart-HarrisR. L.BolstridgeM.DayC. M. J.RuckerJ.WattsR. (2018). Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up.Psychopharmacology (Berl.)235399–408. 10.1007/s00213-017-4771-x
14
Carhart-HarrisR. L.BolstridgeM.RuckerJ.DayC. M. J.ErritzoeD.KaelenM.et al (2016). Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study.Lancet Psychiatry3619–627. 10.1016/S2215-0366(16)30065-7
15
Carhart-HarrisR. L.ErritzoeD.WilliamsT.StoneJ. M.ReedL. J.ColasantiA.et al (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin.Proc. Natl. Acad. Sci. U.S.A.1092138–2143. 10.1073/pnas.1119598109
16
Carhart-HarrisR. L.GiribaldiB.WattsR.Baker-JonesM.Murphy-BeinerA.MurphyR.et al (2021). Trial of psilocybin versus escitalopram for depression.N. Engl. J. Med.3841402–1411. 10.1056/nejmoa2032994
17
Carhart-HarrisR. L.LeechR.HellyerP. J.ShanahanM.FeildingA.TagliazucchiE.et al (2014). The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs.Front. Hum. Neurosci.8:20. 10.3389/fnhum.2014.00020
18
CohenJ. (1988). Statistical power analysis for the behavioral sciences, 2nd Edn. Hillsdale, NJ: Lawrence Erlbaum Associates.
19
DavisA. K.BarrettF. S.MayD. G.CosimanoM. P.SepedaN. D.JohnsonM. W.et al (2021). Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial.JAMA Psychiatry78481–489. 10.1001/jamapsychiatry.2020.3285
20
EleftheriouM. E.ThomasE. (2021). Examining the potential synergistic effects between mindfulness training and psychedelic-assisted therapy.Front. Psychiatry12:707057. 10.3389/fpsyt.2021.707057
21
ErritzoeD.HolstK.FrokjaerV. G.LichtC. L.KalbitzerJ.NielsenF. Ået al (2010). A nonlinear relationship between cerebral serotonin transporter and 5HT-2A receptor binding: An in vivo molecular imaging study in humans.J. Neurosci.303391–3397. 10.1523/JNEUROSCI.2852-09.2010
22
EttrupA.Da Cunha-BangS.McmahonB.LehelS.DyssegaardA.SkibstedA. W.et al (2014). Serotonin 2A receptor agonist binding in the human brain with [11 C]Cimbi-36.J. Cereb. Blood Flow Metab.341188–1196. 10.1038/jcbfm.2014.68
23
EttrupA.SvarerC.McMahonB.da Cunha-BangS.LehelS.MøllerK.et al (2016). Serotonin 2A receptor agonist binding in the human brain with [11C]Cimbi-36: Test–retest reproducibility and head-to-head comparison with the antagonist [18F]altanserin.Neuroimage130167–174. 10.1016/j.neuroimage.2016.02.001
24
FarbN. A. S.SegalZ. V.MaybergH.BeanJ.McKeonD.ZainabF.et al (2007). Attending to the present: Mindfulness meditation reveals distinct neural modes of self-reference.Soc. Cogn. Affect. Neurosci.2313–322. 10.1093/scan/nsm030
25
FinnemaS. J.StepanovV.EttrupA.NakaoR.AminiN.SvedbergM.et al (2014). Characterization of [11C]Cimbi-36 as an agonist PET radioligand for the 5-HT2A and 5-HT2C receptors in the nonhuman primate brain.Neuroimage84342–353. 10.1016/j.neuroimage.2013.08.035
26
FoxK. C. R.DixonM. L.NijeboerS.GirnM.FlomanJ. L.LifshitzM.et al (2016). Functional neuroanatomy of meditation: A review and meta-analysis of 78 functional neuroimaging investigations.Neurosci. Biobehav. Rev.65208–228. 10.1016/j.neubiorev.2016.03.021
27
FrokjaerV. G.MortensenE. L.NielsenF.Å.HaugbolS.PinborgL. H.AdamsK. H.et al (2008). Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder. Biol. Psychiatry63, 569–576. 10.1016/j.biopsych.2007.07.009
28
Garcia-RomeuA.DavisA. K.ErowidF.ErowidE.GriffithsR. R.JohnsonM. W. (2019). Cessation and reduction in alcohol consumption and misuse after psychedelic use.J. Psychopharmacol.331088–1101. 10.1177/0269881119845793
29
GilukT. L. (2009). Mindfulness, big five personality, and affect: A meta-analysis.Pers. Individ. Dif.47805–811. 10.1016/j.paid.2009.06.026
30
GrayJ. A.RothB. L. (2001). Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists.Brain Res. Bull.56441–451. 10.1016/S0361-9230(01)00623-2
31
GriffithsR. R.JohnsonM. W.CarducciM. A.UmbrichtA.RichardsW. A.RichardsB. D.et al (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.J. Psychopharmacol.301181–1197. 10.1177/0269881116675513
32
GriffithsR. R.JohnsonM. W.RichardsW. A.RichardsB. D.JesseR.MacLeanK. A.et al (2018). Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors.J. Psychopharmacol.3249–69. 10.1177/0269881117731279
33
GriffithsR. R.JohnsonM. W.RichardsW. A.RichardsB. D.McCannU.JesseR. (2011). Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects.Psychopharmacology (Berl.)218649–665. 10.1007/s00213-011-2358-5
34
GriffithsR. R.RichardsW. A.JohnsonM. W.McCannU. D.JesseR. (2008). Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.J. Psychopharmacol.22621–632. 10.1177/0269881108094300
35
GriffithsR. R.RichardsW. A.McCannU.JesseR. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.Psychopharmacology (Berl.)187268–283. 10.1007/s00213-006-0457-5
36
GrobC. S.DanforthA. L.ChopraG. S.HagertyM.McKayC. R.HalberstadtA. L.et al (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.Arch. Gen. Psychiatry6871–78. 10.1001/archgenpsychiatry.2010.116
37
GüntherL.LiebscherS.JähkelM.OehlerJ. (2009). Effects of chronic citalopram treatment on 5-HT1A and 5-HT2A receptors in group- and isolation-housed mice.Eur. J. Pharmacol.59349–61. 10.1016/j.ejphar.2008.07.011
38
HayesS. C.LuomaJ. B.BondF. W.MasudaA.LillisJ. (2006). Acceptance and commitment therapy: Model, processes and outcomes.Behav. Res. Ther.441–25. 10.1016/j.brat.2005.06.006
39
HeuschkelK.KuypersK. P. C. (2020). Depression, mindfulness, and psilocybin: Possible complementary effects of mindfulness meditation and psilocybin in the treatment of depression. A review.Front. Psychiatry11:224. 10.3389/fpsyt.2020.00224
40
HölzelB. K.OttU. (2006). Relationships between meditation depth, absorption, meditation practice, and mindfulness: A latent variable approach.J. Transpers. Psychol.38179–199.
41
HölzelB. K.LazarS. W.GardT.Schuman-OlivierZ.VagoD. R.OttU. (2011). How does mindfulness meditation work? Proposing mechanisms of action from a conceptual and neural perspective.Perspect. Psychol. Sci.6537–559. 10.1177/1745691611419671
42
JensenC. G.NiclasenJ.VangkildeS. A.PetersenA.HasselbalchS. G. (2016). General inattentiveness is a long-term reliable trait independently predictive of psychological health: Danish validation studies of the mindful attention awareness scale.Psychol. Assess.28e70–e87. 10.1037/pas0000196
43
JensenC. G.VangkildeS.FrokjaerV.HasselbalchS. G. (2012). Mindfulness training affects attention-Or is it attentional effort?J. Exp. Psychol. Gen.141106–123. 10.1037/a0024931
44
JohnsonM. W.Garcia-RomeuA.GriffithsR. R. (2017). Long-term Follow-up of Psilocybin-facilitated Smoking Cessation.Am. J. Drug Alcohol Abuse4355–60. 10.3109/00952990.2016.1170135
45
JohnsonM. W.Garcia-RomeuA.CosimanoM. P.GriffithsR. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.J. Psychopharmacol.28983–992. 10.1177/0269881114548296
46
JørgensenL. M.WeikopP.VilladsenJ.VisnapuuT.EttrupA.HansenH. D.et al (2018). Cerebral 5-HT release correlates with [11C]Cimbi36 PET measures of 5-HT2A receptor occupancy in the pig brain.J. Cereb. Blood Flow Metab.37425–434. 10.1177/0271678X16629483
47
Kabat-ZinnJ. (1990). Full catastrophe living: Using the wisdom of your mind to face stress, pain and illness.New York, NY: Dell.
48
Kabat-ZinnJ. (2003). Mindfulness-based interventions in context: Past, present, and future.Clin. Psychol. Sci. Pract.10144–156. 10.1093/clipsy/bpg016
49
KengS.-L.SmoskiM. J.RobinsC. J. (2011). Effects of mindfulness on psychological health.Clin. Psychol. Rev.311041–1056. 10.1016/j.cpr.2011.04.006
50
KikenL. G.ShookN. J. (2011). Looking up: Mindfulness increases positive judgments and reduces negativity bias.Soc. Psychol. Personal. Sci.2425–431. 10.1177/1948550610396585
51
MacleanK. A.JohnsonM. W.GriffithsR. R. (2011). Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.J. Psychoph.251453–1461. 10.1177/0269881111420188
52
MadsenM. K.FisherP. M.BurmesterD.DyssegaardA.StenbækD. S.KristiansenS.et al (2019). Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels.Neuropsychopharmacology441328–1334. 10.1038/s41386-019-0324-9
53
MadsenM. K.FisherP. M.StenbækD. S.KristiansenS.BurmesterD.LehelS.et al (2020). A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding.Eur. Neuropsychopharmacol.3371–80. 10.1016/j.euroneuro.2020.02.001
54
MadsenM. K.StenbækD. S.ArvidssonA.ArmandS.Marstrand-JoergensenM. R.JohansenS. S.et al (2021). Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience.Eur. Neuropsychopharmacol.50121–132. 10.1016/j.euroneuro.2021.06.001
55
McCullochD. E.-W.GrzywaczM. Z.MadsenM. K.JensenP. S.OzenneB.ArmandS.et al (2022). Psilocybin-induced mystical-type experiences are related to persisting positive effects: A quantitative and qualitative report.Front. Pharmacol.13:841648. 10.3389/fphar.2022.841648
56
MillièreR. (2017). Looking for the self: Phenomenology, neurophysiology and philosophical significance of drug-induced ego dissolution.Front. Hum. Neurosci.11:245. 10.3389/fnhum.2017.00245
57
MillièreR.Carhart-HarrisR. L.RosemanL.TrautweinF. M.Berkovich-OhanaA. (2018). Psychedelics, meditation, and self-consciousness.Front. Psychol.9:1475. 10.3389/fpsyg.2018.01475
58
MorenoF. A.WiegandC. B.Keolani TaitanoE.DelgadoP. L. (2006). Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.J. Clin. Psychiatry671735–1740. 10.4088/JCP.v67n1110
59
MuthukumaraswamyS. D.ForsythA.LumleyT. (2021). Blinding and expectancy confounds in psychedelic randomized controlled trials.Expert Rev. Clin. Pharmacol.141133–1152. 10.1080/17512433.2021.1933434
60
NicholsD. E. (2016). Psychedelics.Pharmacol. Rev.68264–355. 10.1124/pr.115.011478
61
PahnkeW. (1963). Drugs and mysticism: An analysis of the relationship between psychedelic drugs and the mystical consciousness. Thesis presented to the President and Fellows of Harvard University for the Ph.D. thesis in Religion and Society.Cambridge, MA: Harvard University.
62
PrellerK. H.VollenweiderF. X. (2018). “Phenomenology, structure, and dynamic of psychedelic states,” in Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences, edsHalberstadtA. L.VollenweiderF. X.NicholsD. E. (Berlin: Springer). 10.1007/7854_2016_459
63
QiuT. T.MindaJ. P. (2022). Psychedelic experiences and mindfulness are associated with improved wellbeing. J. Psychoactive Drugs1–11. 10.1080/02791072.2022.2060773
64
RosemanL.NuttD. J.Carhart-HarrisR. L. (2018). Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression.Front. Pharmacol.8:974. 10.3389/fphar.2017.00974
65
RossS.BossisA.GussJ.Agin-LiebesG.MaloneT.CohenB.et al (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial.J. Psychopharmacol.301165–1180. 10.1177/0269881116675512
66
Sanders-BushE.BreedingM.KnothK.TsutsumiM. (1989). Sertraline-induced desensitization of the serotonin 5HT-2 receptor transmembrane sig- naling system.Psychopharmacology (Berl.)9964–69. 10.1007/BF00634454
67
SegalZ.WilliamsJ.TeasdaleJ. (2002). Mindfulness- based cognitive therapy for depression: A new approach to preventing relapse.New York, NY: Guilford.
68
ShapiroS. L.BrownK. W.ThoresenC.PlanteT. G. (2011). The moderation of Mindfulness-based stress reduction effects by trait mindfulness: Results from a randomized controlled trial.J. Clin. Psychol.67267–277. 10.1002/jclp.20761
69
SheehanD. V.LecrubierY.SheehanH. K.AmorimP.JanavsJ.WeillerE.et al (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.J. Clin. Psychiatry5922–33.
70
SloshowerJ.GussJ.KrauseR.WallaceR. M.WilliamsM. T.ReedS.et al (2020). Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame.J. Context. Behav. Sci.1512–19. 10.1016/j.jcbs.2019.11.002
71
SmigielskiL.KometerM.ScheideggerM.KrähenmannR.HuberT.VollenweiderF. X. (2019a). Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat.Sci. Rep.9:14914. 10.1038/s41598-019-50612-3
72
SmigielskiL.ScheideggerM.KometerM.VollenweiderF. X. (2019b). Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects.Neuroimage196207–215. 10.1016/j.neuroimage.2019.04.009
73
SolerJ.ElicesM.FranquesaA.BarkerS.FriedlanderP.FeildingA.et al (2016). Exploring the therapeutic potential of Ayahuasca: Acute intake increases mindfulness-related capacities.Psychopharmacology (Berl.)233823–829. 10.1007/s00213-015-4162-0
74
SpiesM.NasserA.OzenneB.JensenP. S.KnudsenG. M.FisherP. M. (2020). Common HTR2A variants and 5-HTTLPR are not associated with human in vivo serotonin 2A receptor levels.Hum. Brain Mapp.414518–4528. 10.1002/hbm.25138
75
StaceW. (1960). The teachings of the mystics.New York, NY: New American Library.
76
StenbækD. S.MadsenM. K.OzenneB.KristiansenS.BurmesterD.ErritzoeD.et al (2020). Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans.J. Psychopharmacol.35459–468. 10.1177/0269881120959609
77
StuderusE.GammaA.KometerM.VollenweiderF. X. (2012). Prediction of psilocybin response in healthy volunteers.PLoS One7:e30800. 10.1371/journal.pone.0030800
78
SvarerC.MadsenK.HasselbachS. G.PinborgL. H.HaughbølS.FrøkjaerV. G.et al (2005). MR-based automatic delineation of volumes of interest in human brain PET images using probability maps.Neuroimage24969–979. 10.1016/j.neuroimage.2004.10.017
79
UthaugM. V.LancelottaR.van OorsouwK.KuypersK. P. C.MasonN.RakJ.et al (2019). A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psyc.Psychopharmacology (Berl.)2362653–2666. 10.1007/s00213-019-05236-w
80
UthaugM. V.van OorsouwK.KuypersK. P. C.van BoxtelM.BroersN. J.MasonN. L.et al (2018). Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution.Psychopharmacology (Berl.)2352979–2989. 10.1007/s00213-018-4988-3
81
VollenweiderF. X.Vollenweider-ScherpenhuyzenM. F. I.BäblerA.VogelH.HellD. (1998). Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.Neuroreport93897–3902. 10.1097/00001756-199812010-00024
82
WayB. M.CreswellJ. D.EisenbergerN. I.LiebermanM. D. (2010). Dispositional mindfulness and depressive symptomatology: Correlations with limbic and self-referential neural activity during rest.Emotion1012–24. 10.1037/a0018312
83
YathamL. N.LiddleP. F.DennieJ.ShiahI.-S. S.AdamM. J. A.LaneC. J. L.et al (1999). Decrease in Brain Serotonin 2 Receptor Binding in Patients With Major Depression Following Desipramine Treatment A Positron Emission Tomography Study With Fluorine-18–Labeled Setoperone.Arch Gen Psychiatry56705–711. 10.1001/archpsyc.56.8.705
Summary
Keywords
psilocybin, mindfulness, psychedelics, mystical experience, serotonin 2A receptor, [11C]-Cimbi-36, Mindful Attention and Awareness Scale
Citation
Søndergaard A, Madsen MK, Ozenne B, Armand S, Knudsen GM, Fisher PM and Stenbæk DS (2022) Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals. Front. Psychol. 13:948729. doi: 10.3389/fpsyg.2022.948729
Received
20 May 2022
Accepted
16 September 2022
Published
05 October 2022
Volume
13 - 2022
Edited by
Nuno Conceicao, University of Lisbon, Portugal
Reviewed by
Kai-Chun Yang, Taipei Veterans General Hospital, Taiwan; Yasmin Schmid, University of California, San Diego, United States; Szabolcs Lehel, Rigshospitalet, Denmark
Updates
Copyright
© 2022 Søndergaard, Madsen, Ozenne, Armand, Knudsen, Fisher and Stenbæk.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Dea Siggaard Stenbæk, dea@nru.dk
This article was submitted to Psychology for Clinical Settings, a section of the journal Frontiers in Psychology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.